MedTrace Logo

Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19

NCT04387240 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-05-02

No results posted yet for this study

Summary

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.

At this time, there are no specific vaccines or treatments for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments Drugs used to treat malaria infection has shown to be beneficial for many other diseases, including viral infections.

In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab COVID-19 patients. Investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the COVID -19 patients. In improving their condition and clearing the virus load,

Conditions

  • Covid 19 Positive
  • Corona Virus Infection

Interventions

DRUG

Artemisinin / Artesunate

testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative

OTHER

placebo

placebo or sham drug will be given to the second arm

Sponsors & Collaborators

  • Princess Nourah Bint Abdulrahman University

    lead OTHER

Principal Investigators

  • Osama Kentab, MD · Princess Nourah Bint Abdulrahman University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2022-09-30
Completion
2022-12-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04387240 on ClinicalTrials.gov